Smarter cancer care
Exact Sciences brings the promise of precision medicine to life with Oncotype DX®, a full suite of genomic tests.
LEARN MORE
Deborah, an Oncotype DX patient

Landmark RxPONDER Trial Results

Publication in The New England Journal of Medicine confirms that tens of thousands of women with node-positive, early-stage breast cancer can avoid chemotherapy with the Oncotype DX® test.

NCCN Breast Cancer Guidelines

New NCCN Breast Cancer Guidelines recognize Oncotype DX Breast Recurrence Score® as the “preferred” and only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer
Improving Patient Outcomes
Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter" and GPS are pending registered trademarks, of Genomic Health, Inc.
Making cancer care smarter.™